
CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027
Check out the key regulatory decisions set to happen early this year.
There are a number of pending FDA approvals that urologists should keep an eye on as we move through the first half of the year. These include new agents in prostate and bladder cancer, as well as a novel therapeutic for uncomplicated urinary tract infections (uUTIs).



